Akouos, Inc. (NASDAQ:AKUS) has been assigned an average recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $30.00.
A number of brokerages have weighed in on AKUS. HC Wainwright began coverage on shares of Akouos in a report on Monday. They issued a “buy” rating and a $25.00 price objective on the stock. Bank of America cut shares of Akouos from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $20.00 in a report on Tuesday, March 30th. Finally, Zacks Investment Research cut shares of Akouos from a “buy” rating to a “hold” rating in a report on Tuesday, April 27th.
Several large investors have recently bought and sold shares of AKUS. JPMorgan Chase & Co. purchased a new stake in shares of Akouos during the third quarter valued at approximately $125,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Akouos during the third quarter valued at approximately $2,103,000. California State Teachers Retirement System purchased a new stake in shares of Akouos during the third quarter valued at approximately $502,000. Strs Ohio purchased a new stake in shares of Akouos during the third quarter valued at approximately $82,000. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Akouos during the fourth quarter valued at approximately $407,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.
Akouos (NASDAQ:AKUS) last announced its quarterly earnings results on Sunday, March 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. Research analysts anticipate that Akouos will post -2.96 earnings per share for the current year.
Akouos Company Profile
Akouos, Inc, a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.
Featured Article: Momentum Investing
Receive News & Ratings for Akouos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akouos and related companies with MarketBeat.com's FREE daily email newsletter.